The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The San Francisco-based medical genetics firm generated $53.5 million in revenues in the second quarter, beating analysts' consensus estimate of $50.7 million.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.
Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Invitae said this week that it completed its acquisition of Singular Bio on June 19.
Senators said they'll narrow the draft bill containing changes to US patent law before submitting it to the Senate Judiciary Committee in July.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.